Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer

  • Emmanuelle Kempf
  • Ignacio Duran


Muscle-invasive bladder cancer has been associated with a poor prognosis so far, despite the use of standard chemotherapy. The development of new anticancer immune compounds seems a very promising option for such disease both because of indisputable efficacy and good tolerance profile. This article reviews the evidence supporting such statement, according to the tumor stages and the type of innovative compounds. This chapter summarizes the published data, the ongoing trials and the regulatory approvals.


Immunotherapy Checkpoint inhibitors Urothelial carcinoma Drug development 


  1. 1.
    Tian T, et al. The origins of cancer robustness and evolvability. Integr Biol (Camb). 2011;3(1):17–30.CrossRefGoogle Scholar
  2. 2.
    Boon T, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 1971;7:3–25.PubMedGoogle Scholar
  4. 4.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kandoth C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.CrossRefGoogle Scholar
  8. 8.
    Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–34.CrossRefGoogle Scholar
  10. 10.
    Bellmunt J, et al. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii40–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Carbonero R, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5(1):71.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Weiss R, et al. Phase I study of intravesical recombinant fowlpox-GM-CSF (RF-GM-CSF) or recombinant fowlpox-TRICOM (RF-TRICOM) in patients with bladder carcinoma prior to undergoing cystectomy. J Urol. 2015;193(4S):MP72-10.Google Scholar
  13. 13.
    Dash A, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–13.CrossRefPubMedGoogle Scholar
  14. 14.
    Johar RS, et al. Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2013;64(1):52–7.CrossRefPubMedGoogle Scholar
  15. 15.
    David KA, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178(2):451–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Leow JJ, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.CrossRefPubMedGoogle Scholar
  17. 17.
    De Santis M, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Balar AV, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.CrossRefGoogle Scholar
  19. 19.
    Spiess PE, et al. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(10):1240–67.CrossRefGoogle Scholar
  20. 20.
    Alfred Witjes J, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Bellmunt J, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Obara W, et al. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol. 2017;28(4):798–803.PubMedGoogle Scholar
  23. 23.
    Apolo AB, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117–24.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally 3 advanced or metastatic urothelial carcinoma (IMvigor211): a phase 3, open-4 label, multicentre randomised controlled trial. Lancet Oncol. 2018;391(10122):748–57. Scholar
  25. 25.
    Sharma P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Massard C, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–25.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bellmunt J, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Petrylak DP, et al. A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): updated analysis of patients with metastatic urothelial cancer. J Clin Oncol. 2017;35(suppl; abstr):106.CrossRefGoogle Scholar
  29. 29.
    Sundahl N, et al. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. J Transl Med. 2017;15(1):150.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Emmanuelle Kempf
    • 1
  • Ignacio Duran
    • 2
  1. 1.Department of Medical OncologyHenri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de ParisCréteilFrance
  2. 2.Department of Medical OncologyHospital Universitario Marques de Valdecilla, IDIVALCantabriaSpain

Personalised recommendations